Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits

Standard

Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits. / Ozarda, Yesim; Sikaris, Ken; Streichert, Thomas; Macri, Joseph; IFCC Committee on Reference intervals and Decision Limits (C-RIDL).

In: CRIT REV CL LAB SCI, Vol. 55, No. 6, 09.2018, p. 420-431.

Research output: SCORING: Contribution to journalSCORING: Review articleResearch

Harvard

Ozarda, Y, Sikaris, K, Streichert, T, Macri, J & IFCC Committee on Reference intervals and Decision Limits (C-RIDL) 2018, 'Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits', CRIT REV CL LAB SCI, vol. 55, no. 6, pp. 420-431. https://doi.org/10.1080/10408363.2018.1482256

APA

Ozarda, Y., Sikaris, K., Streichert, T., Macri, J., & IFCC Committee on Reference intervals and Decision Limits (C-RIDL) (2018). Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits. CRIT REV CL LAB SCI, 55(6), 420-431. https://doi.org/10.1080/10408363.2018.1482256

Vancouver

Ozarda Y, Sikaris K, Streichert T, Macri J, IFCC Committee on Reference intervals and Decision Limits (C-RIDL). Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits. CRIT REV CL LAB SCI. 2018 Sep;55(6):420-431. https://doi.org/10.1080/10408363.2018.1482256

Bibtex

@article{d41309c306314bcb99538fc1781b5d7b,
title = "Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits",
abstract = "Reference Intervals (RIs) and clinical decision limits (CDLs) are a vital part of the information supplied by laboratories to support the interpretation of numerical clinical pathology results. RIs describe the typical distribution of results seen in a healthy reference population while CDLs are associated with a significantly higher risk of adverse clinical outcomes or are diagnostic for the presence of a specific disease. However, as the two concepts are sometimes confused, there is a need to clarify the differences between these terms and to ensure they are easily distinguished, especially because CDLs have a clinical association with specific diseases and risks, thereby implying that effective clinical interventions are available. It is important to note that, because population-based RIs are derived from the range of values expected in a typical community population, laboratory results that fall outside a RI do not necessarily indicate a disease but rather that additional medical follow-up and/or treatment may be warranted. In contrast, CDLs are associated with a risk of specific adverse outcomes, and are commonly used to interpret laboratory test results, including lipid parameters, glucose, hemoglobin A1c (HbA1c), and tumor markers, to determine risk of disease, to diagnose or to treat. In recent years, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Reference Intervals and Decision Limits (C-RIDL) has focused primarily on RIs and has performed multicenter studies to obtain common RIs. However, the broader responsibility of the Committee, from its name, includes {"}decision limits{"}. C-RIDL now aims to emphasize the importance of the correct use of both RIs and CDLs and to encourage laboratories to specify the appropriate information to clinicians as needed. This review discusses RIs and CDLs in detail, describes the similarities and the differences between these two important tools in laboratory medicine, and clearly explains the processes used to define them. C-RIDL encourages the involvement of laboratory professionals in the establishment of both RIs and CDLs.",
keywords = "Clinical Laboratory Techniques, Humans, Laboratories, Reference Values, Journal Article, Review",
author = "Yesim Ozarda and Ken Sikaris and Thomas Streichert and Joseph Macri and {IFCC Committee on Reference intervals and Decision Limits (C-RIDL)}",
year = "2018",
month = sep,
doi = "10.1080/10408363.2018.1482256",
language = "English",
volume = "55",
pages = "420--431",
journal = "CRIT REV CL LAB SCI",
issn = "1040-8363",
publisher = "informa healthcare",
number = "6",

}

RIS

TY - JOUR

T1 - Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits

AU - Ozarda, Yesim

AU - Sikaris, Ken

AU - Streichert, Thomas

AU - Macri, Joseph

AU - IFCC Committee on Reference intervals and Decision Limits (C-RIDL)

PY - 2018/9

Y1 - 2018/9

N2 - Reference Intervals (RIs) and clinical decision limits (CDLs) are a vital part of the information supplied by laboratories to support the interpretation of numerical clinical pathology results. RIs describe the typical distribution of results seen in a healthy reference population while CDLs are associated with a significantly higher risk of adverse clinical outcomes or are diagnostic for the presence of a specific disease. However, as the two concepts are sometimes confused, there is a need to clarify the differences between these terms and to ensure they are easily distinguished, especially because CDLs have a clinical association with specific diseases and risks, thereby implying that effective clinical interventions are available. It is important to note that, because population-based RIs are derived from the range of values expected in a typical community population, laboratory results that fall outside a RI do not necessarily indicate a disease but rather that additional medical follow-up and/or treatment may be warranted. In contrast, CDLs are associated with a risk of specific adverse outcomes, and are commonly used to interpret laboratory test results, including lipid parameters, glucose, hemoglobin A1c (HbA1c), and tumor markers, to determine risk of disease, to diagnose or to treat. In recent years, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Reference Intervals and Decision Limits (C-RIDL) has focused primarily on RIs and has performed multicenter studies to obtain common RIs. However, the broader responsibility of the Committee, from its name, includes "decision limits". C-RIDL now aims to emphasize the importance of the correct use of both RIs and CDLs and to encourage laboratories to specify the appropriate information to clinicians as needed. This review discusses RIs and CDLs in detail, describes the similarities and the differences between these two important tools in laboratory medicine, and clearly explains the processes used to define them. C-RIDL encourages the involvement of laboratory professionals in the establishment of both RIs and CDLs.

AB - Reference Intervals (RIs) and clinical decision limits (CDLs) are a vital part of the information supplied by laboratories to support the interpretation of numerical clinical pathology results. RIs describe the typical distribution of results seen in a healthy reference population while CDLs are associated with a significantly higher risk of adverse clinical outcomes or are diagnostic for the presence of a specific disease. However, as the two concepts are sometimes confused, there is a need to clarify the differences between these terms and to ensure they are easily distinguished, especially because CDLs have a clinical association with specific diseases and risks, thereby implying that effective clinical interventions are available. It is important to note that, because population-based RIs are derived from the range of values expected in a typical community population, laboratory results that fall outside a RI do not necessarily indicate a disease but rather that additional medical follow-up and/or treatment may be warranted. In contrast, CDLs are associated with a risk of specific adverse outcomes, and are commonly used to interpret laboratory test results, including lipid parameters, glucose, hemoglobin A1c (HbA1c), and tumor markers, to determine risk of disease, to diagnose or to treat. In recent years, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Reference Intervals and Decision Limits (C-RIDL) has focused primarily on RIs and has performed multicenter studies to obtain common RIs. However, the broader responsibility of the Committee, from its name, includes "decision limits". C-RIDL now aims to emphasize the importance of the correct use of both RIs and CDLs and to encourage laboratories to specify the appropriate information to clinicians as needed. This review discusses RIs and CDLs in detail, describes the similarities and the differences between these two important tools in laboratory medicine, and clearly explains the processes used to define them. C-RIDL encourages the involvement of laboratory professionals in the establishment of both RIs and CDLs.

KW - Clinical Laboratory Techniques

KW - Humans

KW - Laboratories

KW - Reference Values

KW - Journal Article

KW - Review

U2 - 10.1080/10408363.2018.1482256

DO - 10.1080/10408363.2018.1482256

M3 - SCORING: Review article

C2 - 30047297

VL - 55

SP - 420

EP - 431

JO - CRIT REV CL LAB SCI

JF - CRIT REV CL LAB SCI

SN - 1040-8363

IS - 6

ER -